OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE
- Country
- 🇦🇺Australia
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.onjcri.org.au
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
- Conditions
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05788081
- Locations
- 🇦🇺
Grampians Health, Ballarat, Victoria, Australia
🇦🇺Eastern Health, Box Hill, Victoria, Australia
🇦🇺Fiona Stanley Hospital, Perth, Western Australia, Australia
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 80
- Registration Number
- NCT05182931
- Locations
- 🇦🇺
Royal Adelaide Hsopital, Adelaide, South Australia, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
🇦🇺Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Combination Immunotherapy in Rare Cancers Under InvesTigation
- Conditions
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 240
- Registration Number
- NCT04969887
- Locations
- 🇳🇿
Auckland City Hospital, Auckland, New Zealand
🇦🇺Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺Fiona Stanley Hospital, Perth, Western Australia, Australia
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 15
- Registration Number
- NCT04962126
- Locations
- 🇦🇺
Ballarat Health Service, Ballarat, Victoria, Australia
🇦🇺Eastern Health, Box Hill, Victoria, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
Bioimaging Study of 89Zr-M7824 in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 5
- Registration Number
- NCT04297748
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
Medical Imaging of Cachexia
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04127981
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
A Trial of KB004 in Patients With Glioblastoma
- First Posted Date
- 2017-12-15
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03374943
- Locations
- 🇦🇺
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
🇦🇺Austin Health, Heidelberg, Victoria, Australia
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 120
- Registration Number
- NCT02923934
- Locations
- 🇦🇺
Blacktown Hospital, Sydney, New South Wales, Australia
🇦🇺Border Medical Oncology Unit, Albury, New South Wales, Australia
🇦🇺Monash Health, Clayton, Victoria, Australia
Pembrolizumab + CVA21 in Advanced NSCLC
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Olivia Newton-John Cancer Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT02824965
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia